Breaking News

CMC Biologics, Symphogen Enter Manufacturing Pact

CMC Biologics has entered into an agreement with Symphogen for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen’s development pipeline. Terms of the agreement were not disclosed.
   
“We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology,” said Mads Laustsen, chief executive officer of CMC Biologics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters